Tandem Diabetes Care (TNDM) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Company Participants Susan Morrison - EVP & Chief Administrative OfficerJohn Sheridan - President and CEOLeigh Vosseller - EVP, CFO & TreasurerMathew Blackman - Managing DirectorAaron Wukmir - Healthcare Equity Research AssociateDavid Roman - Managing DirectorMatthew Taylor - Managing DirectorChris Pasquale - Partner - Medical Devices & SuppliesAnthony Petrone - Managing Director Equity ResearchJoshua Jennings - Managing DirectorIs ...

Company Overview APRIL 30, 2025 Ben diagnosed 2024 Izzy diagnosed 2014 Safe Harbor CAUTIONARY NOTE REGARDING FORWARD-LOOKING STATEMENTS Certain statements in this presentation constitute forward-looking statements, including, without limitation, statements about: the perceived advantages of our products relative to competitive products and technologies; our anticipated growth and other measures of future operating results and financial performance; the development and commercialization of new products; our ...

Tandem Diabetes Care (TNDM) Q1 2025 Earnings Call April 30, 2025 04:30 PM ET Speaker0 Good day, and thank you for standing by. Welcome to the Tandem Diabetes Care First Quarter twenty twenty five Earnings Conference Call. At this time, all participants are in a listen only mode. After the speakers' presentation, there will be a question and answer session. To ask a question during the session, you will need to press 11 on your telephone. Please be advised that today's conference is being recorded. I would n ...

OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Transition Period from to Commission File Number 001-36189 _____________________________________________________________________________________________ Tandem Diabetes Care, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 ____________________________________________________________________________________________ FORM 10-Q _______________________________________________________ ...

Exhibit 99.1 Media Contact: 858-366-6900 media@tandemdiabetes.com Investor Contact: 858-366-6900 IR@tandemdiabetes.com FOR IMMEDIATE RELEASE Tandem Diabetes Care Announces First Quarter 2025 Financial Results • Gross profit: GAAP gross profit was $118.4 million, compared to $94.7 million. GAAP gross margin was 51%, compared to 49%. Non-GAAP gross profit for the first quarter of 2024 was $95.8 million and non-GAAP gross margin was 50%. (1) (1) San Diego, April 30, 2025 - Tandem Diabetes Care, Inc. (Nasdaq: T ...

Tandem Diabetes Care, Inc. (TNDM) shares soared 7.6% in the last trading session to close at $17.61. The move was backed by solid volume with far more shares changing hands than in a normal session. This compares to the stock's 8.5% loss over the past four weeks.Tandem Diabetes scored a strong price increase on investors’ optimism surrounding its impending first quarter 2025 financial results, slated to release on Apr. 30, after the closing bell. In the fourth quarter, the company’s reported sales grew by a ...

文章核心观点 - 公司推出Control - IQ+技术，有望带动股价积极表现，且行业前景良好，但过去一年股价表现不佳 [1][2][3][12] 公司产品动态 - 公司在美国商业推出Control - IQ+技术，兼容t:slim X2胰岛素泵和Tandem Mobi系统，适用于2岁及以上1型糖尿病患者和成人2型糖尿病患者 [1] - Control - IQ+基于公司领先的Control - IQ算法构建，是唯一允许用户设置长达8小时扩展大剂量的AID算法 [5] - Control - IQ+算法新特性包括扩展体重和每日胰岛素总量参数，以及在激活时可进行临时基础率调整 [6] - 2月该技术获FDA批准用于18岁及以上2型糖尿病患者 [7] - 1月公司与弗吉尼亚大学糖尿病技术中心签署多年合作协议，聚焦全自动闭环胰岛素输送系统研发 [11] - 2024年12月公司t:slim X2胰岛素泵与Dexcom G7和Dexcom G6连续血糖监测系统完全兼容，加拿大在保用户可使用 [11] 公司股价及财务情况 - 消息公布后，昨日盘后交易中公司股价微涨1.1% [2] - 过去一年公司股价下跌38.2%，而行业下跌7.5% [12] - 公司市值13.3亿美元，预计2025年每股收益增长率为38.7%，高于行业的15.6%，过去30天2025年每股亏损从2.55美元降至1.17美元 [4] - 公司目前Zacks排名为3（持有） [13] 行业前景 - 据Grand View Research报告，2023年全球胰岛素输送设备市场价值164.3亿美元，预计到2027年复合年增长率为7.9% [8] - 市场增长主要受全球糖尿病患病率上升和技术进步驱动 [9] 同行业其他公司情况 - Masimo Zacks排名为1（强力买入），过去一年股价上涨26.5%，过去30天2024年每股收益预估提高1.2%至4.10美元，过去四个季度均超预期，平均惊喜为17.1%，上一季度为16.6% [13][14] - 波士顿科学Zacks排名为2（买入），过去一年股价上涨47.1%，高于行业的9.5%，过去30天2025年每股收益预估提高2.9%至2.85美元，过去四个季度均超预期，平均惊喜为8.25%，上一季度为7.69% [13][15] - 卡地纳健康Zacks排名为2（买入），过去一年股价上涨17.5%，而行业下跌3.2%，过去30天2025财年每股收益预估提高1.5%至7.94美元，过去四个季度均超预期，平均惊喜为9.6%，上一季度为10.3% [13][16]

Tandem Diabetes Care, Inc.’s (TNDM) fourth-quarter 2024 performance was driven by its impressive range of new products. The company’s impressive strategic initiatives provide a favorable opportunity for growth. However, concerns loom over fierce competition and the adverse impact of macroeconomic challenges.In the past year, this Zacks Rank #3 (Hold) company’s shares have declined 38.5% compared with 8.2% decline of the industry and a 10.6% rise of the S&P 500 composite.The renowned medical device company h ...

If you like what you have just read and want to receive at least 4 exclusive stock tips every week focused on Pharma, Biotech and Healthcare, then join me at my marketplace channel, Haggerston BioHealth . Invest alongside the model portfolio or simply access the investment bank-grade financial models and research. I hope to see you there.The group is for both novice and experienced biotech investors. It provides catalysts to look out for and buy and sell ratings. It also provides product sales and forecasts ...

Tandem Diabetes Care, Inc. (TNDM) posted a fourth-quarter 2024 loss of 44 cents per share compared with the year-ago quarter’s reported loss of 27 cents. The figure missed the Zacks Consensus Estimate of a loss of 25 cents per share.Find the latest EPS estimates and surprises on Zacks Earnings Calendar.On a GAAP basis, the company reported earnings of 1 cent per share compared to the year-ago loss of 46 cents.Full-year 2024 loss was $1.91 per share compared with the year-ago reported loss of $1.57. The figu ...